PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
23
07
2022
revised:
25
08
2022
accepted:
01
09
2022
pubmed:
5
10
2022
medline:
20
12
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Peptide receptor radionuclide therapy (PRRT) is a widely accepted treatment for progressive grade 1 and 2 (G1-2) gastroenteropancreatic neuroendocrine tumors (NET). There is increasing evidence that PRRT is effective for selected patients with well-differentiated (WD) G3 NET, which are now separated from neuroendocrine carcinoma (NEC). These preliminary data have led to prospective PRRT trials currently in progress. This article provides an update of the current role of PRRT for patients with WD-G3 NET, highlighting the importance of patient selection based on molecular imaging phenotype, as well as outlining some potential future directions in this field. Upcoming prospective trials will help define the role, sequencing, and optimization of PRRT to improve outcomes of patients with WD-G3 NET.
Identifiants
pubmed: 36195008
pii: S1471-4892(22)00120-5
doi: 10.1016/j.coph.2022.102293
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102293Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None for Grace Kong. Although not relevant to any material in this manuscript, Professor Hicks is a shareholder of Telix Pharmaceuticals and Founder and Shareholder of PreMIT Pty Ltd.